Combination of | |
---|---|
Vonoprazan | Potassium-competitive acid blocker |
Amoxicillin | Beta-lactam antibiotic |
Clarithromycin | Macrolide antibiotic |
Clinical data | |
Trade names | Vonosap, Voquezna Triple Pak |
License data | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[1][4] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.[1][4]
It was approved for medical use in Japan in 2016,[3] and in the United States in May 2022.[1][2][5][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7][8]